Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

Summary

This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or placebo) for a treatment period of 12-weeks.

Timeline

Start

2008-06

Primary completion

2010-01

Completion

2010-01

Drugs

Indications